Vermont is currently home to 200 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Burlington, Bennington, Berlin and White River Junction. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Central Vermont Medical Center/National Life Cancer Treatment, Berlin, Vermont
Conditions: Previously Treated Non-Small Cell Lung Cancer
Register for Updates
Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection
NCT05776225
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: The University of Vermont Medical Center, Burlington, Vermont
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
Register for Updates
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145
Recruiting
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b LTS (LTS16004) or 1 of the 4 Phase 3 tolebrutinib pivotal trials (GEMINI 1 \[EFC16033\], GEMINI 2 \[EFC16034\], HERCULES \[EFC16645\], or PERSEUS \[EFC16035\]). SUBSTUDY: ToleDYNAMIC substudy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: University of Vermont Medical Center- Site Number : 8400130, Burlington, Vermont
Conditions: Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Register for Updates
Transcranial Magnetic Stimulation to Improve Functioning in Veterans With PTSD
NCT04207346
Recruiting
Posttraumatic Stress Disorder (PTSD) is a common and serious condition affecting many Veterans. There are effective treatments for PTSD, but additional treatments are needed in order to better serve Veterans suffering from PTSD. Transcranial magnetic stimulation is one such promising treatment. It involves use of powerful magnet to stimulate the specific brain regions in Veterans with PTSD. Transcranial magnetic stimulation has been shown effective in treating depression, but currently it is unc... Read More
Gender:
ALL
Ages:
Between 19 years and 70 years
Trial Updated:
03/06/2025
Locations: White River Junction VA Medical Center, White River Junction, VT, White River Junction, Vermont
Conditions: PTSD
Register for Updates
Improving Neurodevelopmental ouTcomes After Prenatal Cannabinoid in uTero Exposure
NCT06423664
Recruiting
The INTACT trial is a multisite pilot feasibility study aimed at testing the effectiveness of the INTACT Intervention program in improving neurodevelopmental outcomes in infants prenatally exposed to cannabinoids. The trial will enroll 20 birthing parent/infant dyads across three sites and will evaluate feasibility endpoints rather than clinical outcomes. The study duration is 22 months, including study start-up, enrollment and intervention, and data analysis and manuscript preparation.
Gender:
ALL
Ages:
7 days and below
Trial Updated:
03/05/2025
Locations: University of Vermont Medical Center, Burlington, Vermont
Conditions: Developmental Delay
Register for Updates
IV Gallium Study for Patients with Cystic Fibrosis Who Have NTM (ABATE Study)
NCT04294043
Recruiting
The purpose of this study is to assess the safety and tolerability of two 5-day infusion cycles of IV gallium in adult patients with CF who are infected with NTM. Funding Source - FDA Office of Orphan Products Development (OOPD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: University of Vermont Medical Center, Burlington, Vermont
Conditions: Nontuberculous Mycobacterium Infection
Register for Updates
His-Bundle Corrective Pacing in Heart Failure
NCT05265520
Recruiting
The investigators aim to prospectively evaluate the efficacy and mechanism of benefit of His-bundle pacing enhanced cardiac resynchronization therapy (His-CRT) vs. cardiac resynchronization therapy (BIV-CRT) in patients with heart failure and right bundle branch block (RBBB).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: University of Vermont, Burlington, Vermont
Conditions: Right Bundle-Branch Block, Heart Failure, His-bundle Pacing, Cardiac Resynchronization Therapy
Register for Updates
Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy
NCT04763356
Recruiting
This is a prospective randomized trial designed to investigate a new care model for patients who suffer from nerve damage from chemotherapy called chemotherapy induced peripheral neuropathy (CIPN). All participants in the study will report their CIPN symptoms daily using a website, app or phone for 12 weeks. In one group the data will be collected and participants will be encouraged to reach out to their treating doctors for uncontrolled symptoms. These participants' doctors can prescribe any tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: University of Vermont, Burlington, Vermont
Conditions: Chemotherapy-induced Peripheral Neuropathy
Register for Updates
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
NCT03926624
Recruiting
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), dependin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: University of Vermont Medical Center, Burlington, Vermont
Conditions: Leukemia, Myeloid, Acute
Register for Updates
CxBladder Surveillance of Intermediate and High-Risk Bladder Cancer Patients
NCT05080998
Recruiting
Surveillance for recurrence of urothelial carcinoma (UC) requires frequent cystoscopy, which is invasive, expensive and time-consuming. An accurate urinary biomarker has the potential to reduce the number of cystoscopies required during post-treatment surveillance. This is a prospective single arm multi-center study using the diagnostic CxBladder test with subjects previously diagnosed positive with primary or recurrent UC and who are undergoing a schedule of investigative cystoscopies and treat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: White River Junction Veterans Affair Medical Center, White River Junction, Vermont
Conditions: Urothelial Bladder Cancer
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: The University of Vermont Medical Center, Burlington, Vermont
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates
Deep Functional Phenotyping of the ALA Lung Health Cohort
NCT06177717
Recruiting
The goal of this observational study is to learn about lung structure and function in a group of 1000 healthy people aged 25 to 35. The main questions it aims to answer are whether people's bodies, environment, and general lung health are associated with: * the structure of the participants lungs' airways, * the structure of blood vessels in the participants lungs and heart, and * the participants lungs' ability to exchange gases. Participants will take four different lung function tests to me... Read More
Gender:
ALL
Ages:
Between 25 years and 35 years
Trial Updated:
02/19/2025
Locations: University of Vermont, Burlington, Vermont
Conditions: Lung Diseases
Register for Updates